Published in Prostate on February 01, 2000
Stat3 promotes metastatic progression of prostate cancer. Am J Pathol (2008) 1.85
Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer (2004) 1.73
The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway. Mol Cell Biol (2003) 1.44
Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol (2001) 1.41
Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells. J Biol Chem (2010) 1.28
Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. Br J Cancer (2007) 1.22
STAT3 regulation of glioblastoma pathogenesis. Curr Mol Med (2009) 1.13
Age-associated chronic diseases require age-old medicine: role of chronic inflammation. Prev Med (2011) 1.09
Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am J Pathol (2003) 1.07
Interleukin-6 mediates G(0)/G(1) growth arrest in hepatocellular carcinoma through a STAT 3-dependent pathway. J Surg Res (2007) 1.03
Prostate cancer and neuroendocrine differentiation: more neuronal, less endocrine? Front Oncol (2015) 1.01
Loss of annexin A1 disrupts normal prostate glandular structure by inducing autocrine IL-6 signaling. Carcinogenesis (2009) 0.94
Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases. Am J Pathol (2009) 0.94
Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer. Am J Pathol (2006) 0.90
PrLZ protects prostate cancer cells from apoptosis induced by androgen deprivation via the activation of Stat3/Bcl-2 pathway. Cancer Res (2011) 0.88
Interleukin-1beta-induced promatrilysin expression is mediated by NFkappaB-regulated synthesis of interleukin-6 in the prostate carcinoma cell line, LNCaP. Neoplasia (2002) 0.85
CCAAT/Enhancer Binding Protein-delta (C/EBP-delta) regulates cell growth, migration and differentiation. Cancer Cell Int (2010) 0.85
Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation. Mol Cancer Ther (2014) 0.84
Piperine, a Bioactive Component of Pepper Spice Exerts Therapeutic Effects on Androgen Dependent and Androgen Independent Prostate Cancer Cells. PLoS One (2013) 0.83
Expression and shedding of endothelial protein C receptor in prostate cancer cells. Cancer Cell Int (2011) 0.83
SH2B1β interacts with STAT3 and enhances fibroblast growth factor 1-induced gene expression during neuronal differentiation. Mol Cell Biol (2014) 0.83
Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells. Br J Cancer (2009) 0.80
Inflammatory suppressive effect of prostate cancer cells with prolonged exposure to transforming growth factor β on macrophage-differentiated cells via downregulation of prostaglandin E2. Oncol Lett (2014) 0.78
Musashi-1 regulates AKT-derived IL-6 autocrinal/paracrinal malignancy and chemoresistance in glioblastoma. Oncotarget (2016) 0.77
Variation and significance of secretory immunoglobulin A, interleukin 6 and dendritic cells in oral cancer. Oncol Lett (2017) 0.75
EGFR-mediated apoptosis via STAT3. Exp Cell Res (2017) 0.75
Recombinant influenza virus polymerase: requirement of both 5' and 3' viral ends for endonuclease activity. J Virol (1994) 3.39
STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells . Prostate (2000) 1.40
Topoisomerase II alpha and topoisomerase II beta genes: characterization and mapping to human chromosomes 17 and 3, respectively. Cancer Res (1992) 1.39
Confirmation of primary active substances from high throughput screening of chemical and biological populations: a statistical approach and practical considerations. J Comb Chem (2000) 1.35
The application of the sinusoidal model to lung cancer patient respiratory motion. Med Phys (2005) 1.30
Investigation of patient, tumour and treatment variables affecting residual motion for respiratory-gated radiotherapy. Phys Med Biol (2006) 1.05
Identification of immediate-early-type cis-response elements in the promoter for the ribonucleotide reductase large subunit from herpes simplex virus type 2. J Virol (1989) 1.04
The role of template-primer interactions in cleavage and initiation by the influenza virus polymerase. J Gen Virol (1995) 1.03
Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170kD and 180kD forms of topoisomerase II. Cancer Res (1990) 1.02
Inhibitory effect of the partially resolved coordination isomers of chromic desferricoprogen on coprogen uptake in Neurospora crassa. J Bacteriol (1986) 0.88
Identification of inhibitors of bacterial transcription/translation machinery utilizing a miniaturized 1536-well format screen. J Biomol Screen (2001) 0.87
Implementation of a continuous, enzyme-coupled fluorescence assay for high-throughput analysis of glutamate-producing enzymes. Anal Biochem (2000) 0.87
Immediate early and functional AP-1 cis-response elements are involved in the transcriptional regulation of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10). Virus Res (1992) 0.85
Expression of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is required for virus growth and neoplastic transformation. J Gen Virol (1992) 0.85
Development of a carbon dioxide-capture assay in microtiter plate for aspartyl-beta-hydroxylase. Anal Biochem (1999) 0.83
Selective inhibition of bacterial dihydroorotate dehydrogenases by thiadiazolidinediones. Biochem Pharmacol (2000) 0.82
A scintillation proximity assay for rna detection. Anal Biochem (2001) 0.78
Hypericum perforatum L. extract - novel photosensitizer against human bladder cancer cells. J Photochem Photobiol B (2006) 0.78
Cytometry microchip using polymer-based saltbridge electrodes. Conf Proc IEEE Eng Med Biol Soc (2004) 0.75